This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Karlson, E W Articles by Fortin, P R Search for Related Content PubMed PubMed Citation Articles by Karlson, E W Articles by Fortin, P R Pubmed/NCBI databases Medline Plus Health Information Lupus Social Bookmarking                         What's this?

Validation of a systemic lupus activity questionnaire (SLAQ) for population studies

Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Robert B. Brigham Arthritis and Musculoskeletal Clinical Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

L H Daltroy

Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Robert B. Brigham Arthritis and Musculoskeletal Clinical Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

C Rivest

Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Robert B. Brigham Arthritis and Musculoskeletal Clinical Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA, Deceased

R Ramsey-Goldman

Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

E A Wright

Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Robert B. Brigham Arthritis and Musculoskeletal Clinical Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

A J Partridge

Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Robert B. Brigham Arthritis and Musculoskeletal Clinical Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

M H Liang

Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Robert B. Brigham Arthritis and Musculoskeletal Clinical Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

P R Fortin

Toronto Western Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

The goal of this work was to develop an economical way of tracking disease activity for large groups of systemic lupus erythematosus (SLE) patients in clinical studies. A Systemic Lupus Activity Questionnaire (SLAQ) was developed to screen for possible disease activity using items from the Systemic Lupus Activity Measure (SLAM) and tested for its measurement properties. The SLAQ was completed by 93 SLE patients just prior to a scheduled visit. At the visit, a rheumatologist, blinded to SLAQ results, examined the subject and completed a SLAM. Associations among SLAQ, and SLAM (omitting laboratory items) and between individual items from each instrument were assessed with Pearson correlations. Correlations between pairs of instruments were compared using Student’s t-tests. The mean score across all 24 SLAQ items was 11.5 (range 0 -33); mean SLAM without labs was 3.0 (range 0 -13). The SLAQ had a moderately high correlation with SLAM-nolab (r = 0.62, P < 0.0001). Correlations between patient-clinician matched pairs of items ranged from r = 0.06 to 0.71. Positive predictive values for the SLAQ ranged from 56 to 89% for detecting clinically significant disease activity. In studies of SLE, symptoms suggesting disease can be screened by self-report using the SLAQ and then verified by further evaluation.

Key Words: SLE • disease activity • self-assessment • clinical trials • clinimetrics • outcome

Lupus, Vol. 12, No. 4, 280-286 (2003)
DOI: 10.1191/0961203303lu332oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. J. COLANGELO, J. E. POPE, and C. PESCHKEN The Minimally Important Difference for Patient Reported Outcomes in Systemic Lupus Erythematosus Including the HAQ-DI, Pain, Fatigue, and SF-36 J Rheumatol, October 1, 2009; 36(10): 2231 - 2237. [Abstract] [Full Text] [PDF]

				C. A. PESCHKEN, S. J. KATZ, E. SILVERMAN, J. E. POPE, P. R. FORTIN, C. PINEAU, C. D. SMITH, H. O. ARBILLAGA, D. D. GLADMAN, M. UROWITZ, et al. The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort J Rheumatol, June 1, 2009; 36(6): 1200 - 1208. [Abstract] [Full Text] [PDF]

				F. WOLFE, M. PETRI, G. S. ALARCON, J. GOLDMAN, E. F. CHAKRAVARTY, R. S. KATZ, and E. W. KARLSON Fibromyalgia, Systemic Lupus Erythematosus (SLE), and Evaluation of SLE Activity J Rheumatol, January 1, 2009; 36(1): 82 - 88. [Abstract] [Full Text] [PDF]

				S. Y. Yuen and J. E. Pope Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials Rheumatology, September 1, 2008; 47(9): 1367 - 1372. [Abstract] [Full Text] [PDF]

				C. Lee, O. Almagor, D. D. Dunlop, S. Manzi, S. Spies, A. B. Chadha, and R. Ramsey-Goldman Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids Rheumatology, January 1, 2006; 45(1): 53 - 60. [Abstract] [Full Text] [PDF]